These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16629772)

  • 1. Gender change and its impact on the course of multiple sclerosis.
    Reske D; Haupt WF; Petereit HF
    Acta Neurol Scand; 2006 May; 113(5):347-9. PubMed ID: 16629772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation.
    Trojano M; Paolicelli D; Bellacosa A; Cataldo S
    Neurol Sci; 2003 Dec; 24 Suppl 5():S268-70. PubMed ID: 14652786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone treatment in multiple sclerosis: a pilot study.
    Sicotte NL; Giesser BS; Tandon V; Klutch R; Steiner B; Drain AE; Shattuck DW; Hull L; Wang HJ; Elashoff RM; Swerdloff RS; Voskuhl RR
    Arch Neurol; 2007 May; 64(5):683-8. PubMed ID: 17502467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
    Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
    Minden S; Hoaglin D; Jureidini S; Hadden L; Frankel D; Komatsuzaki Y; Outley J
    Mult Scler; 2008 Jun; 14(5):640-55. PubMed ID: 18566028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic criteria of multiple sclerosis with reference to different clinical forms].
    Dimitri D
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):914-28. PubMed ID: 11787356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of iron dysregulation in the pathogenesis of multiple sclerosis: an Egyptian study.
    Abo-Krysha N; Rashed L
    Mult Scler; 2008 Jun; 14(5):602-8. PubMed ID: 18408021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the natural history of MS: the need for complete data and rigorous definitions.
    Tremlett H; Zhao Y; Devonshire V
    Mult Scler; 2008 Sep; 14(8):1142-3; author reply 1144-7. PubMed ID: 18701573
    [No Abstract]   [Full Text] [Related]  

  • 12. Palliative care in patients with severe multiple sclerosis: two case reports and a survey among German MS neurologists.
    Kümpfel T; Hoffmann LA; Pöllmann W; Rieckmann P; Zettl UK; Kühnbach R; Borasio GD; Voltz R
    Palliat Med; 2007 Mar; 21(2):109-14. PubMed ID: 17344259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the natural history of MS: the need for complete data and rigorous definitions.
    Confavreux C
    Mult Scler; 2008 Apr; 14(3):289-91. PubMed ID: 18420777
    [No Abstract]   [Full Text] [Related]  

  • 14. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
    Pulizzi A; Rovaris M; Judica E; Sormani MP; Martinelli V; Comi G; Filippi M
    Arch Neurol; 2007 Aug; 64(8):1163-8. PubMed ID: 17698707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression in familial and nonfamilial MS.
    Koch M; Uyttenboogaart M; Heerings M; Heersema D; Mostert J; De Keyser J
    Mult Scler; 2008 Apr; 14(3):300-6. PubMed ID: 18208881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plasma immunoadsorption treatment of malignant multiple sclerosis with severe and prolonged relapses].
    de Andrés C; Anaya F; Giménez-Roldán S
    Rev Neurol; 2000 Apr 1-15; 30(7):601-5. PubMed ID: 10859735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
    Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
    Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of multiple sclerosis].
    Simó M
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.